Sampaio-Maia B, Moreira-Rodrigues M, Serrão P, Pestana M
Institute of Pharmacology and Therapeutics, Faculty of Medicine, University of Porto, Alameda Prof. Hernani Monteiro, 4200-319, Porto, Portugal.
Life Sci. 2006 Feb 9;78(11):1246-55. doi: 10.1016/j.lfs.2005.06.028. Epub 2005 Sep 22.
The present study evaluated the possible role of the renal dopaminergic system in the sodium retention of HgCl2-induced nephrotic syndrome. The time courses of urinary excretion of sodium, protein, dopamine and the precursor l-3,4-dihydroxyphenylalanine (L-Dopa) were evaluated in HgCl2-treated and control rats up to day 21. The renal aromatic l-amino acid decarboxylase (AADC) activity, the enzyme responsible for the synthesis of renal dopamine, was evaluated during negligible proteinuria accompanied with enhanced sodium retention (day 7), increased proteinuria accompanied with greatest sodium retention (day 14) as well as during increased proteinuria accompanied with negative sodium balance (day 21). Also, the influence of volume expansion (VE, 5% bw) and the effects of the D1-like agonist fenoldopam (10 microg kg bw(-1) min(-1)) on natriuresis and on proximal tubular Na+,K+-ATPase activity were examined on day 14. The daily urinary dopamine output and urinary dopamine/L-Dopa ratios were reduced in HgCl2-treated rats from day 2 and beyond. This was accompanied by a marked decrease in renal AADC throughout the study. During VE, the fenoldopam-induced inhibition of proximal tubular Na+,K+-ATPase activity was similar between HgCl2-treated and control rats. However, the urinary sodium excretion during fenoldopam infusion was markedly increased by 60% to 120% in control rats but was not altered in HgCl2-treated rats. It is concluded that HgCl2 nephrosis is associated with a blunted renal dopaminergic system activity. However, the lack of renal dopamine in HgCl2 nephrosis does not appear to be related with the overall renal sodium retention in a state of proteinuria.
本研究评估了肾多巴胺能系统在氯化汞诱导的肾病综合征钠潴留中的可能作用。在长达21天的时间里,对氯化汞处理的大鼠和对照大鼠的钠、蛋白质、多巴胺及其前体L-3,4-二羟基苯丙氨酸(L-多巴)的尿排泄时间进程进行了评估。在蛋白尿可忽略且伴有钠潴留增强(第7天)、蛋白尿增加且伴有最大钠潴留(第14天)以及蛋白尿增加且伴有负钠平衡(第21天)期间,评估了负责肾多巴胺合成的肾芳香族L-氨基酸脱羧酶(AADC)活性。此外,在第14天研究了容量扩张(VE,体重的5%)的影响以及D1样激动剂非诺多泮(10μg·kg bw⁻¹·min⁻¹)对利钠作用和近端肾小管Na⁺,K⁺-ATP酶活性的影响。从第2天及以后,氯化汞处理的大鼠每日尿多巴胺排出量和尿多巴胺/L-多巴比值降低。在整个研究过程中,这伴随着肾AADC的显著降低。在容量扩张期间,非诺多泮诱导的近端肾小管Na⁺,K⁺-ATP酶活性抑制在氯化汞处理的大鼠和对照大鼠之间相似。然而,在非诺多泮输注期间,对照大鼠的尿钠排泄量显著增加了60%至120%,而氯化汞处理的大鼠则没有改变。结论是,氯化汞肾病与肾多巴胺能系统活性减弱有关。然而,氯化汞肾病中肾多巴胺缺乏似乎与蛋白尿状态下的总体肾钠潴留无关。